GLP

Researchers at the University of Pennsylvania have used artificial intelligence and data from online forums to identify potential side effects of retatrutide, an unapproved GLP-1 weight-loss drug still in development. The study highlights a new way to detect adverse reactions before regulators or manufacturers can, drawing attention as interest in next-generation obesity medications keeps growing.

Doctors are warning that people taking GLP-1 weight-loss and diabetes drugs such as Ozempic face heightened health risks during the current heat wave. The drugs can contribute to dehydration, and patients may not feel thirsty or may experience nausea and vomiting, making it harder to stay hydrated. Medical experts are advising users to drink water regularly, avoid excessive heat, and seek medical attention if they develop dizziness or other symptoms of dehydration.

Eli Lilly is exploring opportunities in aesthetic medicine, as growing numbers of patients taking its GLP-1 weight-loss drugs deal with side effects such as sagging or loose skin after rapid weight loss. The move would position the Indianapolis-based drugmaker to serve patients seeking procedures to address changes in appearance tied to medications like Zepbound and Mounjaro.

Drugs like Ozempic and Wegovy were originally developed and described as obesity treatments for patients with medical need, but they are increasingly marketed and used as lifestyle drugs for customers seeking cosmetic or wellness benefits. Commentators note this reframing raises questions about access for people with genuine medical need, pricing, and how the pharmaceutical industry positions these medicines.

A new study finds that people who stop taking GLP-1 weight-loss and diabetes drugs, such as Ozempic and Wegovy, may face an increased risk of heart attack and stroke. The findings suggest the cardiovascular benefits of these medications depend on continued use, raising questions about how patients should manage long-term treatment.

The Federal Reserve's latest Beige Book reports that GLP-1 weight-loss drugs such as Ozempic are changing consumer demand, with businesses noting reduced consumption of poultry and alcohol as users eat and drink less. The observation signals that the medications are now having measurable effects on the broader economy, not just the healthcare sector.

GLP-1 medications such as Ozempic and Wegovy are being discussed as a new approach to weight loss, moving beyond diet and exercise as the standard advice. Johns Hopkins University is among the institutions weighing in on how these drugs work and what their rise means for obesity treatment. The conversation centers on effectiveness, costs, and how widely these drugs will change care.

A new study reports that about one in six children taking GLP-1 medications, such as Ozempic and Wegovy, developed nutritional deficiencies while on the drugs. The findings raise concerns that appetite suppression and reduced intake may leave some children short on key nutrients, prompting calls for closer monitoring of children prescribed these increasingly used weight-loss medications.

GLP-1 weight-loss drugs such as Ozempic and Wegovy are being linked to changes in sleep health, with researchers examining how significant weight loss affects sleep apnoea and other sleep disorders. The trend is prompting sleep medicine specialists to rethink diagnosis rates, treatment demand and how therapies like CPAP may be used as more patients take these medications.

Attention in Italy is turning to satiety drugs after a major recall of GLP-1 weight-loss medications was reported by Il Messaggero. The article outlines what is known about the recall, the potential risks for patients, and whether Italy could be affected. Readers are discussing the safety of these popular appetite-suppressing treatments.

Health experts say weight loss drugs such as GLP-1 medications could offer benefits beyond slimming, potentially helping treat women's reproductive health issues. The suggestion points to a possible new use for a class of medicines already in high demand, and it is drawing attention to how obesity-related treatments might intersect with conditions like polycystic ovary syndrome and fertility problems.

A functional medicine expert is cautioning that high doses of GLP-1 weight-loss and diabetes drugs may affect more than appetite, potentially disrupting other bodily processes beyond food cravings. The warning, reported by Fox News, adds to ongoing debate about the safety and long-term effects of medications such as Ozempic and Wegovy as their use continues to expand.

A new study has connected the use of GLP-1 weight-loss and diabetes medications in children with nutritional deficiencies, according to Scripps News, which published an interactive report on the findings. The drugs, widely prescribed to minors amid rising childhood obesity rates, may leave young users short of key nutrients. The findings add to ongoing debate over the safety and supervision of GLP-1 treatment in pediatric patients.

A mouse study found that olive oil given before glucose blunted the early blood sugar spike and slowed stomach emptying, with the hormones glucagon and GLP-1 acting as partly redundant backup mechanisms. The effect held in diabetic mice. Researchers caution the finding is preliminary and has not yet been shown to apply to humans.

Young people taking GLP-1 receptor agonists, the class of drugs that includes Ozempic and Wegovy, are showing nutritional deficiencies, according to coverage in medical news outlets. The reports add to ongoing scrutiny of the drugs' safety in children and adolescents, with clinicians urged to monitor patients' nutrient intake while on the medications.

The next generation of obesity medicines is taking shape beyond today's GLP-1 injections. Developers are working on oral GLP-1 pills, multi-receptor therapies and drug combinations designed to preserve muscle while patients lose weight. The push reflects a race to improve on blockbuster treatments like Ozempic and Wegovy, whose weight-loss effects can come with muscle loss and a need for lifelong injections.

A review of CPHI Milan 2026 highlights how pharmaceutical manufacturing standards and the surge around GLP-1 drugs are reshaping the nutraceuticals industry. Exhibitors and analysts reportedly discussed tighter quality expectations and shifting consumer interest as companies in the supplements sector adapt their strategies in response to the weight-loss drug boom.

GLP-1 injections, widely used for diabetes and weight loss, have been recalled nationwide in the United States, prompting consumers to check whether their products are affected. USA Today is directing readers to a list of the impacted lots, and searches about the safety recall are climbing as patients seek guidance on what to do with their medication.

People taking Ozempic and similar GLP-1 weight-loss and diabetes drugs are reporting brittle or damaged nails, in addition to hair loss previously flagged as a possible side effect. The reports are anecdotal for now, and researchers have not established a confirmed link, but the growing volume of patient accounts is drawing attention to side effects beyond the drugs' intended use.

Drugmakers Novo Nordisk and Eli Lilly presented findings at the Aging Research and Drug Discovery meeting suggesting their GLP-1 drugs, already used for diabetes and obesity, may slow biological aging. The reports point to markers indicating slower aging processes in patients, fueling debate over whether these medicines could extend beyond weight loss into longevity treatment, and drawing wide attention from the research community and investors.

Retatrutide, an experimental weight-loss injection developed by Eli Lilly, is drawing widespread searches and media explainers in the US, UK and Australia. Outlets are walking readers through what the drug is, how it differs from existing GLP-1 treatments like Ozempic and tirzepatide, and what trial results suggest about its potential for obesity treatment.

Blood sugar control is drawing attention in Italy after researchers announced a lab-created probiotic that produces GLP-1 and reduces blood glucose levels. Related coverage examines why GLP-1 drugs are insufficient without dietary education, and how stress can raise glucose readings. It coincides with European Commission health initiatives, including Europe's first Screening Week launched from Milan and new recommendations as cardiovascular disease causes a third of EU deaths.

New Zealand dairy giant Fonterra is moving to serve the nutritional needs of people taking weight-loss medications such as GLP-1 drugs, which reduce appetite and can leave users short of protein and key nutrients. The company is positioning high-protein dairy products to fill that gap, tapping into one of the fastest-growing trends in global food and health.

Public health coverage is drawing together two related topics: the possible mental health effects of GLP-1 weight-loss and diabetes drugs, and the role of exercise for women going through menopause. Listeners are weighing reported mood changes linked to GLP-1 medications against growing evidence that physical activity can ease menopause symptoms such as hot flashes, sleep problems and weight gain.

Interest is growing in retatrutide, Eli Lilly's experimental obesity and diabetes drug, which follows in the footsteps of tirzepatide and semaglutide. Discussion centres on its triple-hormone mechanism and trial results suggesting greater weight loss than existing GLP-1 medicines. Commentators frame it as the next step in the fast-expanding market for weight-loss injections, though it remains under development and not yet approved.

European Union regulators have issued a positive recommendation for approving Eli Lilly's oral weight loss medication, a pill developed as an alternative to injectable GLP-1 treatments. The recommendation moves the drug closer to European market authorization, expanding access to obesity treatment in tablet form. Financial and health news outlets are covering the decision given the booming demand for weight loss drugs and Eli Lilly's leading position in the market.

Novo Nordisk has received approval in Singapore for Wegovy as the first treatment for MASH, a liver disease involving fibrosis. It marks a new indication for the weight-loss drug beyond obesity and diabetes. Attention centres on how semaglutide could expand into treating fatty liver disease globally.

Millions of people taking GLP-1 weight-loss and diabetes medications such as Ozempic and Mounjaro are being reminded that good nutrition matters while on the drugs. Because the medications suppress appetite, experts warn users risk losing muscle mass and missing key nutrients if they do not plan meals carefully, with guidance circulating on protein intake and balanced eating.

Suppliers in the nutrition industry are stressing that companion products aimed at people taking GLP-1 weight-loss and diabetes drugs should complement the medication rather than compete with it. The discussion, reported by Nutrition Insight, centers on how food, supplement and ingredient makers can support users of drugs like Ozempic and Wegovy, who often face reduced appetite and nutritional gaps.

New reporting examines how GLP-1 medications, widely used for weight loss and diabetes, may influence mental health, particularly depression and anxiety. The discussion focuses on whether these drugs have positive or negative psychological effects for patients taking them. Health outlets are weighing the evidence as use of GLP-1 drugs continues to expand globally.

Designers are presenting spring-summer 2027 collections dominated by sheer fabrics, lingerie-inspired pieces, lace, and skin-revealing cutouts, making the body the season's central theme. Commenters are debating whether the trend reflects or pushes back against the cultural mood shaped by the rise of GLP-1 weight loss medications, and what it signals about shifting attitudes toward body image in fashion.

Ingredients firms ADM, Cargill and Synergy Flavours say the rapid rise of GLP-1 weight-loss drugs is changing how nutrition products are formulated. Companies are adapting to users' reduced appetites and altered tastes, developing smaller portions and products richer in protein and micronutrients to help people on the medications meet their nutritional needs.

With GLP-1 weight-loss drugs reshaping eating habits, the food industry is rethinking portion sizes, nutrient density and sensory satisfaction. As appetite suppression reduces how much people eat, manufacturers and nutrition experts are examining how smaller portions can still deliver adequate protein, vitamins and enjoyable eating experiences. The debate spans product reformulation, packaging and how meals should be designed for people on medications like Ozempic and Wegovy.

Food and nutrition companies are developing products tailored to people using GLP-1 weight-loss drugs, with protein, fiber and taste identified as the key drivers of this next wave of companion nutrition. As appetite suppression from medications like Ozempic and Wegovy reduces how much users eat, manufacturers see demand for nutrient-dense foods that help patients maintain muscle mass and digestive health.

News coverage is examining how nutrition and dietary guidance are changing as GLP-1 weight-loss and diabetes drugs such as Ozempic and Wegovy become widely used. The discussion centres on how these medications affect appetite, eating habits, and the advice dietitians and doctors give patients, and what balanced nutrition should look like for people on the drugs.

U.S. News & World Report has released a new survey examining what makes GLP-1 telehealth programs work, finding that patient priorities and ongoing support are central drivers of success. The findings point to sustained coaching and follow-up care, rather than medication access alone, as decisive factors for people using telehealth services for weight-loss drugs.